Literature DB >> 11230439

In vitro evolution of the human immunodeficiency virus type 1 gag-protease region and maintenance of reverse transcriptase resistance following prolonged drug exposure.

S La Seta Catamancio1, M P De Pasquale, P Citterio, S Kurtagic, M Galli, S Rusconi.   

Abstract

We studied the human immunodeficiency virus type 1 phenotypic and genotypic profiles of a dual drug-resistant isolate (isolate 14aPost-DR) selected for zidovudine (ZDV) and lamivudine (3TC) resistance and then cultured in the presence of 3TC and a protease inhibitor: indinavir (IDV), ritonavir, or KNI-272. The IDV-treated virus was highly resistant to 3TC, ZDV, and IDV and accumulated protease mutations at positions M46I and V82F. A change from alanine to valine was observed in 4 of 10 clones in the P2 position of the p7-p1 Gag-protease cleavage site, linked to position M46I in the dominant viral quasispecies. Previous 3TC resistance did not impair the development of additional mutations in the protease and Gag-protease cleavage regions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11230439      PMCID: PMC87885          DOI: 10.1128/JCM.39.3.1124-1129.2001

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  27 in total

1.  Loss of antiviral effect owing to zidovudine and lamivudine double resistance in HIV-1-infected patients in an ongoing open-label trial.

Authors:  S Rusconi; M P De Pasquale; L Milazzo; G Moscatelli; E Bulgheroni; P Citterio; A d'Arminio-Monforte; M Moroni; M Galli
Journal:  Antivir Ther       Date:  1997-01

2.  HIV-1 drug resistance in newly infected individuals.

Authors:  D Boden; A Hurley; L Zhang; Y Cao; Y Guo; E Jones; J Tsay; J Ip; C Farthing; K Limoli; N Parkin; M Markowitz
Journal:  JAMA       Date:  1999 Sep 22-29       Impact factor: 56.272

3.  Standardized microtiter assay for determination of syncytium-inducing phenotypes of clinical human immunodeficiency virus type 1 isolates.

Authors:  A J Japour; S A Fiscus; J M Arduino; D L Mayers; P S Reichelderfer; D R Kuritzkes
Journal:  J Clin Microbiol       Date:  1994-09       Impact factor: 5.948

4.  Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor.

Authors:  D D Ho; T Toyoshima; H Mo; D J Kempf; D Norbeck; C M Chen; N E Wideburg; S K Burt; J W Erickson; M K Singh
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

5.  Human immunodeficiency virus type 1 cloning vectors for antiretroviral resistance testing.

Authors:  J Martinez-Picado; L Sutton; M P De Pasquale; A V Savara; R T D'Aquila
Journal:  J Clin Microbiol       Date:  1999-09       Impact factor: 5.948

6.  Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1.

Authors:  J Martinez-Picado; A V Savara; L Sutton; R T D'Aquila
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

Review 7.  HIV-1 protease inhibitors. A review for clinicians.

Authors:  S G Deeks; M Smith; M Holodniy; J O Kahn
Journal:  JAMA       Date:  1997-01-08       Impact factor: 56.272

8.  In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors.

Authors:  J H Condra; W A Schleif; O M Blahy; L J Gabryelski; D J Graham; J C Quintero; A Rhodes; H L Robbins; E Roth; M Shivaprakash
Journal:  Nature       Date:  1995-04-06       Impact factor: 49.962

9.  In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies.

Authors:  H Jacobsen; M Hänggi; M Ott; I B Duncan; S Owen; M Andreoni; S Vella; J Mous
Journal:  J Infect Dis       Date:  1996-06       Impact factor: 5.226

10.  Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors.

Authors:  M Tisdale; R E Myers; B Maschera; N R Parry; N M Oliver; E D Blair
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

View more
  6 in total

1.  Structural basis for coevolution of a human immunodeficiency virus type 1 nucleocapsid-p1 cleavage site with a V82A drug-resistant mutation in viral protease.

Authors:  Moses Prabu-Jeyabalan; Ellen A Nalivaika; Nancy M King; Celia A Schiffer
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

2.  Mechanism of substrate recognition by drug-resistant human immunodeficiency virus type 1 protease variants revealed by a novel structural intermediate.

Authors:  Moses Prabu-Jeyabalan; Ellen A Nalivaika; Keith Romano; Celia A Schiffer
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

3.  Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor.

Authors:  Nancy M King; Moses Prabu-Jeyabalan; Ellen A Nalivaika; Piet Wigerinck; Marie-Pierre de Béthune; Celia A Schiffer
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

4.  HIV-1 Protease and Substrate Coevolution Validates the Substrate Envelope As the Substrate Recognition Pattern.

Authors:  Ayşegül Ozen; Türkan Haliloğlu; Celia A Schiffer
Journal:  J Chem Theory Comput       Date:  2012-02-14       Impact factor: 6.006

5.  Highly Drug-Resistant HIV-1 Protease Mutant PRS17 Shows Enhanced Binding to Substrate Analogues.

Authors:  Johnson Agniswamy; Daniel W Kneller; Rowan Brothers; Yuan-Fang Wang; Robert W Harrison; Irene T Weber
Journal:  ACS Omega       Date:  2019-05-17

Review 6.  Genetic and phylogenetic evolution of HIV-1 in a low subtype heterogeneity epidemic: the Italian example.

Authors:  Luigi Buonaguro; Maria Tagliamonte; Maria Lina Tornesello; Franco M Buonaguro
Journal:  Retrovirology       Date:  2007-05-21       Impact factor: 4.602

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.